Moderna Inc. ($MRNA) Stock Forecast: Up 7.9% Today

What is Moderna Inc.?

Moderna Inc. (MRNA) is a biotechnology company recognized for its innovative mRNA technology, notably its COVID-19 vaccine.

Why is Moderna Inc. going up?

MRNA stock is up 7.9% on Dec 5, 2025 20:41

• Moderna's stock experienced a surge today after a significant study from France verified the safety and effectiveness of its COVID-19 vaccine, reassuring investors about the company's primary product.
• This upward momentum was also backed by the company surpassing its 20-day moving average, indicating a short-term uptrend and optimistic earnings estimate adjustments.
• Institutional engagement with Moderna showed a mixed picture, with one entity reducing its position notably, while another entity acquired a considerable number of shares in the second quarter.
• Overall, the encouraging developments concerning the COVID-19 vaccine efficacy and technical signals played a role in the strong bullish movement witnessed in Moderna's stock today.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

BioAge Labs stock rating upgraded by Morgan Stanley on promising BGE-102 data

Morgan Stanley upgraded BioAge Labs Inc (NASDAQ:BIOA) to Equalweight from Underweight and increased its price target to $12.00 after promising initial clinical data for its BGE-102 drug candidate. The drug showed robust biomarker reductions suggesting potential for cardiovascular risk reduction. BioAge Labs also announced positive interim results from its Phase 1 clinical trial of BGE-102, an oral NLRP3 inhibitor, demonstrating it was well-tolerated across various dose levels with mild to moderate adverse events.

https://www.investing.com/news/analyst-ratings/bioage-labs-stock-rating-upgraded-by-morgan-stanley-on-promising-bge102-data-93CH-4394102

Why Is Moderna (MRNA) Stock Rocketing Higher Today

Moderna's stock jumped after a major long-term study from France confirmed its COVID-19 vaccine is safe and effective. The study, analyzing data from 28 million people, showed vaccinated individuals had a significantly lower risk of death from COVID and any cause. This positive news reassured investors about the company's key product despite the stock being down year-to-date.

https://finviz.com/news/247302/why-is-moderna-mrna-stock-rocketing-higher-today

Moderna (MRNA) Recently Broke Out Above the 20-Day Moving Average

Moderna (MRNA) has demonstrated a short-term bullish trend after crossing above its 20-day moving average, a key technical indicator for traders. The company also shows a strong positive outlook in earnings estimate revisions, with 9 upward revisions for the current fiscal year. Investors are encouraged to watch MRNA for potential further gains due to this combination of technical and fundamental strength.

https://finviz.com/news/245667/moderna-mrna-recently-broke-out-above-the-20-day-moving-average

Norges Bank Buys Shares of 3,439,999 Moderna, Inc. $MRNA

Norges Bank acquired 3,439,999 shares of Moderna, Inc. (NASDAQ:MRNA) valued at approximately $94.91 million during the second quarter, representing 0.88% of the company's stock. Other institutional investors also adjusted their holdings in Moderna, with 75.33% of the stock owned by hedge funds and institutions. The article also provides details on recent analyst ratings, share price performance, and Moderna's latest earnings report.

https://www.marketbeat.com/instant-alerts/filing-norges-bank-buys-shares-of-3439999-moderna-inc-mrna-2025-12-04/

Skandinaviska Enskilda Banken AB publ Trims Position in Moderna, Inc. $MRNA

Skandinaviska Enskilda Banken AB publ has significantly reduced its stake in Moderna, Inc. (NASDAQ:MRNA) by 98.5% in the second quarter, valuing their remaining 1,002 shares at $28,000. This move comes amidst other institutional investors modifying their holdings in Moderna, and various analysts issuing "Hold," "Buy," and "Sell" ratings for the stock, with a current consensus of "Reduce." Moderna recently reported better-than-expected quarterly earnings, though its revenue was down year-over-year.

https://www.marketbeat.com/instant-alerts/filing-skandinaviska-enskilda-banken-ab-publ-trims-position-in-moderna-inc-mrna-2025-12-04/

Trending Today

Omnicom Group Inc. ($OMC) Stock Forecast: Up 5.0% Today

Cognex Corporation ($CGNX) Stock Forecast: Down 4.6% Today

Dayforce, Inc. ($DAY) Stock Forecast: Up 0.3% Today

Uber Technologies Inc. ($UBER) Stock Forecast: Down 8.2% Today

XRP ($XRP) Crypto Forecast: Down 5.0% Today

Manhattan Associates, Inc. ($MANH) Stock Forecast: Down 2.6% Today

Quidelortho Corpoation ($QDEL) Stock Forecast: Up 5.0% Today

Intuitive Surgical Inc. ($ISRG) Stock Forecast: Down 2.8% Today

Amylyx Pharmaceuticals ($AMLX) Stock Forecast: Down 5.1% Today

DENTSPLY SIRONA Inc. ($XRAY) Stock Forecast: Up 2.4% Today

Moderna Inc. Price History

05.11.2025 - MRNA Stock was up 7.9%

• Moderna's stock experienced a surge today after a significant study from France verified the safety and effectiveness of its COVID-19 vaccine, reassuring investors about the company's primary product.
• This upward momentum was also backed by the company surpassing its 20-day moving average, indicating a short-term uptrend and optimistic earnings estimate adjustments.
• Institutional engagement with Moderna showed a mixed picture, with one entity reducing its position notably, while another entity acquired a considerable number of shares in the second quarter.
• Overall, the encouraging developments concerning the COVID-19 vaccine efficacy and technical signals played a role in the strong bullish movement witnessed in Moderna's stock today.

05.11.2025 - MRNA Stock was up 6.3%

• Moderna's positive market movement is linked to its surpassing of the 20-day moving average, indicating a favorable short-term trend and capturing the attention of traders.
• While a decrease in the stake held by Skandinaviska Enskilda Banken AB publ initially raised some concerns, the sizeable acquisition of shares by Norges Bank, alongside optimistic earnings forecast adjustments, likely bolstered investor trust in the stock.
• Despite a year-over-year revenue decline, Moderna's quarterly earnings surpassing expectations might have reassured investors regarding the company's growth prospects, playing a role in the current market positivity.
• In summary, Moderna's stock appears to have been driven upwards today by a blend of technical strength, encouraging earnings projections, and institutional investments.

03.10.2025 - MRNA Stock was down 5.8%

• Moderna (MRNA) stock saw a downward trend today, which could be linked to profit-taking following recent gains.
• A decline in short interest suggests a potential loss of market backing, potentially contributing to the stock's decline.
• Worries about the upcoming Q3 earnings drop may have impacted investor confidence and fueled the bearish movement.
• Despite recent fluctuations, Moderna's long-term outlook and innovative mRNA technology show promise, positioning it as a stock worth monitoring for future developments.

04.10.2025 - MRNA Stock was down 5.1%

• MRNA stock faced a bearish trajectory attributed to various factors:
• Declining demand for the COVID-19 vaccine affecting the company's earnings forecast.
• Recent setbacks in clinical trials overshadowing positive pipeline updates and causing unease among investors.
• Despite prior stock price surges, the trend in earnings estimate revisions may not support further upward momentum.
• Reduced short interest suggesting potential waning market backing, contributing to the stock's downward pressure.

04.10.2025 - MRNA Stock was down 5.1%

• MRNA stock experienced a bearish movement likely due to:
• Earnings pressure and pipeline setbacks as waning COVID-19 vaccine demand impacts its outlook.
• Recent clinical setbacks overshadowing positive pipeline news, causing investor concern.
• Market sentiment shifting as short interest in MRNA shares decreases, indicating potential loss of market support.
• The combination of these factors contributed to the strong bearish movement in MRNA stock as investors reevaluate the company's growth prospects amidst evolving market conditions.

31.09.2025 - MRNA Stock was up 12.4%

• Moderna (MRNA) saw a robust upward movement, with a notable 13.9% increase in its stock price.
• A 12.38% decline in short interest hints at growing market support and favorable sentiment towards the company.
• Despite predictions of a Q3 earnings decrease, Moderna's stock outperformed the broader market, indicating investor confidence in its future growth.
• The recent trend in earnings estimate revisions may not sustain the stock's current upward trajectory, signaling potential volatility ahead.

30.09.2025 - MRNA Stock was up 8.0%

• Despite expectations of a decline in Q3 earnings, Moderna (MRNA) surprised the market with a strong bullish movement, outperforming the broader market.
• The bullish movement could be attributed to investor optimism surrounding the company's potential for future vaccine developments and revenue growth.
• The market may be reacting positively to Moderna's resilience and ability to navigate challenges, showcasing confidence in its long-term prospects.
• This unexpected bullish movement showcases how investor sentiment and market performance can sometimes diverge from analysts' expectations.

30.09.2025 - MRNA Stock was up 17.5%

• The decrease in short interest suggests a rising positive sentiment towards Moderna's stock.
• Despite anticipated Q3 earnings decline, Moderna outperformed the broader market, demonstrating resilience and investor confidence.
• The optimistic market movement may be due to excitement about the company's innovative mRNA technology and potential future developments in the healthcare sector.
• Investors appear to be placing more importance on Moderna's long-term growth potential rather than short-term earnings fluctuations, fueling the bullish trend in the stock.

11.10.2025 - MRNA Stock was up 5.0%

• The company recorded a third-quarter loss that was notably under projections, signaling a solid financial performance.
• Moderna's quarterly sales surpassed estimates, highlighting its robust revenue generation.
• The favorable outcomes in earnings and revenue suggest a promising financial trajectory for Moderna, potentially bolstering investor confidence and fueling the upward trend in its stock price.
• The revised sales forecast, coupled with the exceptional financial results, likely played a significant role in driving Moderna's stock price upward today.

28.09.2025 - MRNA Stock was down 5.1%

• Moderna's stock (MRNA) experienced a strong bearish movement today, closing at $26.85 with a -2.33% change from the previous day.
• The market reacted negatively to the news that Moderna halted its CMV vaccine program due to the vaccine falling short in preventing infection in a Phase 3 trial.
• Investors might be concerned about the company's future pipeline and potential setbacks in developing new vaccines.
• This news highlights the volatility and risks associated with biotech stocks, where clinical trial results can significantly impact stock performance.

20.10.2025 - MRNA Stock was down 5.2%

• Moderna stock saw a decrease in value after two notable revelations concerning its finances and business strategy.
• Market sentiment towards the company may have turned pessimistic, reflecting potential apprehensions regarding its future financial trajectory and strategic decisions.
• Investors could be adopting a watchful stance on Moderna until further details emerge on the implications of these announcements for the company's expansion opportunities.

04.11.2025 - MRNA Stock was up 5.2%

• Moderna's stock has surpassed its 20-day moving average, indicating a short-term bullish trend that has caught traders' attention.
• Institutional activity surrounding Moderna has been a mix, with one entity reducing its stake significantly as another acquired a substantial number of shares.
• Analyst opinions on Moderna vary, with some recommending a "Hold" position, but the overall sentiment is positive due to strong earnings estimates.
• The increase in Moderna's stock price could be due to technical strength from crossing the moving average and favorable fundamental factors like earnings outlook, despite varying institutional investor actions.